MDGL - Madrigal Pharmaceuticals Inc Stock Price, Fair Value and News

$282.86-12.50 (-4.23%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

MDGL Price Action

Last 7 days

-5.3%

Last 30 days

-12.2%

Last 90 days

-19.6%

Trailing 12 Months

34.1%

MDGL RSI Chart

MDGL Valuation

Market Cap

6.3B

Price/Earnings (Trailing)

-16.04

Price/Sales (Trailing)

19.79

Price/Free Cashflow

-15.84

MDGL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MDGL Fundamentals

MDGL Revenue

Revenue (TTM)

317.4M

Rev. Growth (Yr)

886.77%

Rev. Growth (Qtr)

66.18%

MDGL Earnings

Earnings (TTM)

-391.6M

Earnings Growth (Yr)

50.36%

Earnings Growth (Qtr)

-23.26%

MDGL Profitability

Return on Equity

-55.1%

Return on Assets

-39.29%

Free Cashflow Yield

-6.31%

MDGL Investor Care

Shares Dilution (1Y)

4.18%

Diluted EPS (TTM)

-17.89

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	317.4M	0	0	0
2024	45.6M	90.4M	135.3M	180.1M
2021	2.6M	1.5M	743.0K	0
2020	9.9M	8.1M	6.1M	4.3M
2019	10.0M	11.8M	11.8M	11.0M
2018	1.2M	2.3M	4.9M	7.7M
2017	0	0	0	558.0K
2016	0	0	0	0
2012	0	0	0	0
2011	12.4M	9.9M	8.2M	7.6M
2010	0	101.1M	58.0M	14.8M
2009	0	0	0	144.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.

WEBSITE	madrigalpharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	92

Madrigal Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Madrigal Pharmaceuticals Inc? What does MDGL stand for in stocks?

MDGL is the stock ticker symbol of Madrigal Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Madrigal Pharmaceuticals Inc (MDGL)?

As of Wed May 14 2025, market cap of Madrigal Pharmaceuticals Inc is 6.28 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MDGL stock?

You can check MDGL's fair value in chart for subscribers.

Is Madrigal Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether MDGL is over valued or under valued. Whether Madrigal Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Madrigal Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MDGL.

What is Madrigal Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 14 2025, MDGL's PE ratio (Price to Earnings) is -16.04 and Price to Sales (PS) ratio is 19.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MDGL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Madrigal Pharmaceuticals Inc's stock?

In the past 10 years, Madrigal Pharmaceuticals Inc has provided 0.132 (multiply by 100 for percentage) rate of return.